Tirzepatide 10 mg

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Beligas - US
WAREHOUSE USA Warehouse 2
SUBSTANCE GIP/GLP-1 RA

Introducing Tirzepatide, a cutting-edge synthetic peptide designed to effectively lower glucose levels. This innovative compound works by enhancing both first- and second-phase insulin secretion while simultaneously reducing glucagon levels, all in a glucose-dependent manner.

Clinical studies have shown that Tirzepatide can significantly slow gastric emptying, lower fasting and post-meal glucose levels, curb appetite, and support weight loss in individuals with type 2 diabetes. Moreover, it holds promise for improving insulin sensitivity.

The unique structure of this peptide includes a C20 fatty diacid linked via a hydrophilic connector at the lysine residue in position 20. This design allows Tirzepatide to strongly bind with plasma albumin, thereby extending its half-life.

GLP-1 receptors (GLP-1R) are distributed throughout the body, particularly in pancreatic beta-cells and the gastrointestinal tract. These receptors play a vital role in managing glucose levels and are linked to the onset of type 2 diabetes. By enhancing glucose-stimulated insulin secretion, slowing gastric transit, and lowering plasma glucagon levels, GLP-1R signaling promotes weight loss through appetite-regulating pathways in the brain. Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are crucial peptide hormones that help maintain glucose equilibrium by stimulating insulin secretion from pancreatic beta-cells, with GIP primarily driving the insulinotropic response to food intake.

While the exact mechanism of action for Tirzepatide remains partially elusive, its dual targeting of GIP and GLP-1R is likely pivotal in its effectiveness for glycemic control and weight management. Research indicates that combining GIP with a GLP-1R agonist produces a more pronounced insulin response and a greater reduction in glucagon secretion compared to administering either hormone alone. Tirzepatide exhibits a robust binding affinity for both GIP and GLP-1R, with laboratory studies showing its receptor binding affinity for GIP is on par with that of native GIP, although it binds to GLP-1R five times less effectively than native GLP-1. By activating the GLP-1R signaling pathway, Tirzepatide promotes glucose-dependent insulin secretion through either the GIP receptor (GIPR) or the GLP-1R. However, additional research is essential to fully understand the implications of GIPR activation on its glycemic control and weight management effects, as the existing evidence from both preclinical and clinical studies remains mixed.